Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands

被引：0
|
作者：
Heisen, M.
Treur, M. J.
van der Hel, W. S.
Groot, M. T.
Verheggen, B. G.
机构：
[1] Pharmerit Europe, Rotterdam, Netherlands
[2] Novartis Pharma BV, Arnhem, Netherlands
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [21] Predicting response to fingolimod in patients with relapsing-remitting multiple sclerosis
    Giuliani, M.
    Prosperini, L.
    Fanelli, F.
    Hirsch, M. N.
    De Angelis, F.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 306 - 306
  • [22] COST MINIMIZATION ANALYSIS OF FINGOLIMOD COMPARED TO NATALIZUMAB IN PATIENTS WITH RELAPSE REMITTING MULTIPLE SCLEROSIS IN THE NETHERLANDS
    Verheggen, B.
    Treur, M.
    Groot, M.
    VALUE IN HEALTH, 2011, 14 (07) : A323 - A323
  • [23] ECONOMIC EVALUATION OF NATALIZUMAB VERSUS FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SWEDEN
    Alexopoulos, S. T.
    Deniz, B.
    Walker, A. R.
    Arnold, R.
    Bates, D.
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [24] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [25] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [26] Efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis in real world clinical practice
    Totaro, R.
    Costantino, G.
    Bellantonio, P.
    Danni, M.
    Di Carmine, C.
    Fantozzi, R.
    Cerqua, R.
    Fuiani, A.
    Mundi, C.
    Ruggieri, S.
    Marini, C.
    Provinciali, L.
    Carolei, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 267 - 267
  • [27] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
    Baroncini, D.
    Ghezzi, A.
    Stefanin, C.
    Zaffaroni, M.
    Annovazzi, P.
    Baldini, S.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
  • [28] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
  • [29] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [30] Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
    Derfuss, T.
    Bergvall, N. K.
    Sfikas, N.
    Tomic, D. L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1687 - 1691
12345